Sacubitril-Valsartan: A Cost-Effective Solution for Heart Failure Management

By Staff Writer

October 7, 2023

A New Class IA Recommendation for Heart Failure Treatment

Heart failure, a major cause of hospital admissions in the U.S., comes with high morbidity, mortality, and financial costs. Recent advances in pharmacotherapy for heart failure with reduced ejection fraction (HFrEF) have given rise to new disease-modifying therapies. One such novel angiotensin receptor neprilysin inhibitor (ARNI) is sacubitril-valsartan.

The PARADIGM-HF clinical trial found that sacubitril-valsartan reduced the risk of cardiovascular death or hospitalization due to heart failure (HF), among ambulatory patients with an HFrEF of 40% or less. This makes it a highly cost-effective treatment option.

Broadening the Scope of Sacubitril-Valsartan

In February 2021, the U.S. Food and Drug Administration expanded the labelling of sacubitril-valsartan to include all adult patients with chronic HF. This decision was based on the understanding that the benefits are most evident in patients with left ventricular ejection fraction (LVEF) below normal. However, the upper bound of below-normal EF is not well defined.

A recent economic evaluation of treatment with sacubitril-valsartan vs renin-angiotensin system inhibitors (RASis) in patients with HF across a broader range of EFs found the treatment to be of high economic value for patients with EF≤50%. It showed intermediate value up to an EF of 60% or less before accounting for any price concessions that payers may receive.

Commentary from Cohen at al., mentioned that the economic value of sacubitril-valsartan is comparable to sodium-glucose cotransporter 2 inhibitors (SGLT2is). Both are dependent on drug price. SGLT2is were estimated to be intermediate value costing $126 500 and $139 000 per quality-adjusted life year in those with LVEFs of 40% to 49% and 50% to 59%, respectively. However, these analyses do not consider the affordability of the medications for individuals. Economic assessments of these novel medications suggest they could add billions to US healthcare spending. Without efforts to lower drug prices, the use of costly, intermediate- to low-value care may be reinforced.

Conclusion
Sacubitril-valsartan increases quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio consistent with high economic value for patients inclusive of reduced and mildly reduced EFs (≤50%). The data analysis of 13,264 total patients showed that for those with EFs of 60% or less, sacubitril-valsartan could potentially add 0.53 quality-adjusted life-years (QALYs). This would come at an incremental lifetime cost of $40,892 compared to RASi, resulting in an ICER of $76,852 per QALY. Therefore, it is estimated to be of at least intermediate value when using the current undiscounted wholesale acquisition cost price across a broad HF population with EFs below normal, when below normal is defined as an EF of 60% or less.

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.